Gajdos et al conducted a trial to determine the efficacy of IVIG or plasma exchange in 87 patients with myasthenia gravis crisis. Primary endpoint of the study includes improvement of myasthenic muscular score. Fourteen adverse effects were observed after receiving plasma exchange and only one patient receiving IVIG experienced a headache.
All IVIG products are interchangeable.
Use of IVIG outside of these indications is not recommended. Dosing should be consistent with the manufacturer's recommendations based on indication. Arsura E. Experience with intravenous immunoglobulin in myasthenia gravis. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Recommendations for off-label use of intravenously administered immunoglobin preparations.